【步长制药：预计2025年上半年净利润同比增110.88%-205.94%】步长制药公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增加2.55亿元到4.81亿元，同比增加115.40%到217.67%。

金融界2025-07-14

步长制药公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增加2.55亿元到4.81亿元，同比增加115.40%到217.67%。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551903761?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-14 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551903761","market":"sh","top_or_hot":-1,"title":"【步长制药：预计2025年上半年净利润同比增110.88%-205.94%】步长制药公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增加2.55亿元到4.81亿元，同比增加115.40%到217.67%。","media":"金融界","content":"<div>\n<p>步长制药公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增加2.55亿元到4.81亿元，同比增加115.40%到217.67%。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/07/14161051674594.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【步长制药：预计2025年上半年净利润同比增110.88%-205.94%】步长制药公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增加2.55亿元到4.81亿元，同比增加115.40%到217.67%。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【步长制药：预计2025年上半年净利润同比增110.88%-205.94%】步长制药公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增加2.55亿元到4.81亿元，同比增加115.40%到217.67%。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-14 16:10 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/07/14161051674594.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>步长制药公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增加2.55亿元到4.81亿元，同比增加115.40%到217.67%。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/07/14161051674594.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603858","symbol_name":"步长制药","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/07/14161051674594.shtml","article_id":"2551903761","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551903761","pubTimestamp":1752480619,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"步长制药公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增加2.55亿元到4.81亿元，同比增加115.40%到217.67%。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"603858":"步长制药"},"translate_title":"[Buchang Pharmaceutical: It is expected that the net profit in the first half of 2025 will increase by 110.88%-205.94% year-on-year] Buchang Pharmaceutical announced that it is expected that the net profit attributable to the owners of the parent company in the first half of 2025 will be about 488 million to 708 million yuan. Compared with the same period last year, it will increase by 257 million yuan to 477 million yuan, a year-on-year increase of 110.88% to 205.94%. It is estimated that the net profit attributable to the owners of the parent company after deducting non-recurring gains and l","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603858":1},"content_text":"步长制药公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增加2.55亿元到4.81亿元，同比增加115.40%到217.67%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551903761","isCrawlerRequest":true}